Skip to main content

NYSE:BSX - Boston Scientific Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.53
  • Forecasted Upside: 11.53 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 1 Strong Buy Ratings
$41.72
▲ +0.17 (0.41%)
1 month | 3 months | 12 months
Get New Boston Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$46.53
▲ +11.53% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $46.53, with a high forecast of $52.00 and a low forecast of $43.00. The average price target represents a 11.53% upside from the last price of $41.72.

Buy

The current consensus among 17 contributing investment analysts is to buy stock in Boston Scientific. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2019
  • 1 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2020
  • 2 strong buy ratings
  • 21 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2020
  • 2 strong buy ratings
  • 20 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/20/2020
  • 2 strong buy ratings
  • 19 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/18/2020
  • 2 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/16/2021
  • 1 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/17/2021
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $51.00Low
i
4/29/2021TruistBoost Price Target$42.00 ➝ $50.00Low
i
4/29/2021Canaccord GenuityBoost Price TargetBuy$44.00 ➝ $49.00Low
i
4/29/2021Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $51.00Low
i
4/29/2021Wells Fargo & CompanyBoost Price TargetIn-Line ➝ Overweight$42.00 ➝ $50.00Low
i
4/29/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$39.00 ➝ $45.00Low
i
4/21/2021Atlantic SecuritiesInitiated CoverageOverweight$52.00High
i
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$52.00High
i
2/12/2021Needham & Company LLCBoost Price TargetBuy$43.00 ➝ $46.00Low
i
2/4/2021Raymond JamesBoost Price TargetStrong-Buy$39.00 ➝ $43.00Low
i
2/3/2021Piper SandlerBoost Price TargetIn-Line ➝ Overweight$46.00 ➝ $48.00High
i
2/1/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
i
12/15/2020Morgan StanleyBoost Price TargetOverweight$40.00 ➝ $43.00Low
i
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
i
12/8/2020BTIG ResearchReiterated RatingBuyLow
i
11/18/2020TruistLower Price Target$47.00 ➝ $44.00Medium
i
11/18/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$46.00 ➝ $43.00Medium
i
11/18/2020Smith Barney CitigroupLower Price Target$46.00 ➝ $43.00High
i
11/18/2020Wells Fargo & CompanyLower Price TargetOverweight$44.00 ➝ $41.00High
i
11/18/2020Morgan StanleyLower Price TargetOverweight$41.00 ➝ $40.00High
i
11/17/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $43.00High
i
Rating by Michael Matson at Needham & Company LLC
10/29/2020Morgan StanleyLower Price TargetOverweight$48.00 ➝ $41.00High
i
9/17/2020TruistInitiated CoverageBuy$47.00 ➝ $47.00High
i
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$46.00Medium
i
7/30/2020Stifel NicolausBoost Price TargetBuy$45.00 ➝ $47.00Low
i
Rating by Rick Wise at Stifel Nicolaus
7/30/2020Jefferies Financial GroupBoost Price TargetBuy$43.00 ➝ $46.00Low
i
7/30/2020CitigroupBoost Price TargetBuy$44.00 ➝ $46.00Medium
i
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $43.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
7/30/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $48.00Medium
i
7/29/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
i
Rating by Michael Matson at Needham & Company LLC
7/29/2020OppenheimerBoost Price TargetMarket Perform$41.00 ➝ $43.00Medium
i
6/24/2020Stifel NicolausReiterated RatingBuy$45.00Low
i
Rating by Rick Wise at Stifel Nicolaus
5/13/2020ArgusBoost Price TargetBuy$40.00 ➝ $42.00Low
i
4/30/2020CSFBBoost Price TargetOutperform$42.00 ➝ $43.00High
i
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$40.00 ➝ $41.00Low
i
4/30/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $43.00Low
i
4/30/2020CitigroupBoost Price TargetBuy$40.00 ➝ $42.00Medium
i
4/30/2020UBS GroupLower Price TargetBuy$50.00 ➝ $45.00Medium
i
4/30/2020Stifel NicolausBoost Price TargetBuy$35.00 ➝ $45.00Medium
i
4/30/2020Raymond JamesBoost Price TargetStrong-Buy$42.00 ➝ $43.00High
i
4/30/2020OppenheimerReiterated RatingHold$46.00 ➝ $41.00Low
i
4/29/2020BTIG ResearchReiterated RatingBuy$44.00Low
i
Rating by Marie Thibault at BTIG Research
4/29/2020Needham & Company LLCReiterated RatingBuy$46.00Low
i
Rating by Michael Matson at Needham & Company LLC
4/23/2020SunTrust BanksLower Price TargetBuy$28.00 ➝ $25.00Low
i
4/22/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$40.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
4/9/2020Raymond JamesLower Price TargetStrong-Buy$49.00 ➝ $42.00High
i
4/2/2020Piper SandlerReiterated RatingBuyLow
i
Rating by Matthew O'Brien at Piper Sandler
4/2/2020Needham & Company LLCLower Price TargetBuy$53.00 ➝ $43.00Medium
i
4/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-Buy$46.00 ➝ $38.00High
i
3/27/2020CitigroupLower Price TargetBuy$48.00 ➝ $40.00Low
i
3/24/2020Stifel NicolausLower Price TargetBuy$47.00 ➝ $30.00High
i
3/23/2020StephensLower Price TargetOverweight$48.00 ➝ $35.00High
i
Rating by Chris Cooley at Stephens
3/9/2020CfraUpgradeBuy ➝ Strong-Buy$50.00 ➝ $47.00Low
i
3/6/2020Credit Suisse GroupLower Price TargetOutperform$51.00 ➝ $46.00High
i
3/4/2020CitigroupInitiated CoverageBuy$48.00High
i
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$46.00Low
i
2/6/2020BTIG ResearchInitiated CoverageBuy$46.00Low
i
2/6/2020Canaccord GenuityReiterated RatingBuy$58.00Low
i
1/15/2020CowenReiterated RatingBuy$52.00Medium
i
Rating by Josh Jennings at Cowen Inc
1/14/2020Piper SandlerReiterated RatingBuyLow
i
Rating by Matthew O'Brien at Piper Sandler
12/30/2019CowenBoost Price TargetOutperform$47.00 ➝ $52.00Low
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$50.00 ➝ $55.00Low
i
12/19/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$53.00Low
i
Rating by Michael Matson at Needham & Company LLC
12/17/2019Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $51.00Medium
i
Rating by David Lewis at Morgan Stanley
12/16/2019Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $52.00Low
i
10/25/2019GuggenheimSet Price TargetBuy$53.00N/A
i
Rating by Christopher Pasquale at Guggenheim
10/23/2019Needham & Company LLCReiterated RatingBuy$53.00Medium
i
Rating by Michael Matson at Needham & Company LLC
10/14/2019Raymond JamesLower Price TargetStrong-Buy$50.00 ➝ $48.00Low
i
9/30/2019StephensSet Price TargetBuy$48.00Low
i
Rating by Chris Cooley at Stephens
9/6/2019Stifel NicolausSet Price TargetBuy$47.00High
i
Rating by Rick Wise at Stifel Nicolaus
9/5/2019JPMorgan Chase & Co.Initiated CoverageOverweightMedium
i
9/3/2019BarclaysReiterated RatingOverweight$48.00High
i
8/30/2019Stifel NicolausSet Price TargetBuy$46.00Low
i
Rating by Rick Wise at Stifel Nicolaus
8/29/2019Morgan StanleySet Price TargetBuy$50.00Low
i
Rating by David Lewis at Morgan Stanley
7/31/2019SVB LeerinkSet Price TargetBuy$50.00Low
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/25/2019Raymond JamesBoost Price TargetStrong-Buy$48.00 ➝ $50.00Medium
i
7/24/2019Needham & Company LLCSet Price TargetBuy$46.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/24/2019BTIG ResearchSet Price TargetBuy$46.00Low
i
Rating by Sean Lavin at BTIG Research
7/24/2019Piper Jaffray CompaniesSet Price TargetBuy$50.00Low
i
Rating by Matthew O'Brien at Piper Jaffray Companies
6/27/2019Stifel NicolausBoost Price TargetBuy ➝ In-Line$44.00 ➝ $46.00Medium
i
6/27/2019Canaccord GenuityBoost Price TargetBuy$43.00 ➝ $46.00Medium
i
6/27/2019Jefferies Financial GroupBoost Price TargetBuy ➝ Positive$44.00 ➝ $48.00Medium
i
6/27/2019Piper Jaffray CompaniesBoost Price TargetOverweight$42.00 ➝ $50.00Medium
i
6/18/2019Wells Fargo & CompanyBoost Price TargetOutperform$42.00 ➝ $45.00Medium
i
5/13/2019Evercore ISIUpgradeIn-Line ➝ Outperform$36.20Low
i
5/13/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
i
4/25/2019BTIG ResearchReiterated RatingBuyHigh
i
4/17/2019Canaccord GenuityLower Price TargetBuy ➝ Buy$45.00 ➝ $43.00Medium
i
2/13/2019ArgusBoost Price TargetBuy$43.00 ➝ $45.00Medium
i
Rating by Jasper Hellweg at Argus
2/11/2019Canaccord GenuityReiterated RatingBuy$45.00Medium
i
2/8/2019SunTrust BanksReiterated RatingBuy$47.00Low
i
2/8/2019GuggenheimReiterated RatingBuy$48.00Low
i
2/6/2019Needham & Company LLCReiterated RatingBuy$43.00Low
i
1/8/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$42.00Low
i
11/27/2018UBS GroupInitiated CoverageBuy ➝ Buy$45.00High
i
11/21/2018OppenheimerReiterated RatingHoldLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/21/2018BTIG ResearchReiterated RatingBuyLow
i
11/20/2018SunTrust BanksBoost Price TargetBuy$44.00Low
i
11/19/2018StephensReiterated RatingIn-Line ➝ Market Perform$40.00Medium
i
11/16/2018GuggenheimBoost Price TargetBuy$45.00Low
i
10/26/2018ArgusBoost Price TargetBuy ➝ Buy$41.00 ➝ $43.00Low
i
Rating by Jasper Hellweg at Argus
10/25/2018Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $42.00Low
i
10/25/2018BTIG ResearchReiterated RatingBuy$45.00Medium
i
10/24/2018OppenheimerSet Price TargetHold$38.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/22/2018CowenSet Price TargetBuy$39.00 ➝ $42.00Low
i
10/16/2018BTIG ResearchReiterated RatingBuy$45.00High
i
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$43.00High
i
10/15/2018Royal Bank of CanadaBoost Price TargetTop Pick$42.00High
i
10/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$38.00 ➝ $48.00Low
i
9/25/2018OppenheimerReiterated RatingHoldMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/17/2018Wells Fargo & CompanyBoost Price TargetOutperform$38.00 ➝ $42.00Low
i
9/7/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$39.00 ➝ $43.00Low
i
9/5/2018ArgusBoost Price TargetBuy$41.00Low
i
9/4/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$40.00 ➝ $41.00Low
i
9/4/2018Jefferies Financial GroupUpgradeHold ➝ Buy$34.00 ➝ $42.00Low
i
7/27/2018GuggenheimReiterated RatingBuy$43.00Low
i
7/26/2018Stifel NicolausReiterated RatingBuy$37.00Low
i
7/26/2018Jefferies Financial GroupReiterated RatingHold$34.00Low
i
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $38.00Low
i
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$38.00Low
i
7/23/2018Royal Bank of CanadaBoost Price TargetTop Pick$36.00Low
i
7/23/2018SunTrust BanksBoost Price TargetBuy$39.00Low
i
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$36.00High
i
7/6/2018Needham & Company LLCReiterated RatingStrong-BuyMedium
i
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$38.00Low
i
6/7/2018ArgusBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.00Medium
i
5/1/2018CitigroupBoost Price TargetBuy ➝ Buy$32.00 ➝ $34.00Low
i
4/26/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$32.00 ➝ $34.00Low
i
4/26/2018Jefferies Financial GroupReiterated RatingHold$31.00Low
i
4/26/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$35.00 ➝ $36.00Low
i
4/26/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $33.00Low
i
4/26/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $32.00Low
i
4/25/2018Canaccord GenuityReiterated RatingBuy$36.00Low
i
4/5/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$30.00 ➝ $34.00Low
i
3/27/2018Needham & Company LLCReiterated RatingBuy$35.00High
i
3/19/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00Low
i
3/5/2018Royal Bank of CanadaReiterated RatingTop Pick$32.00Medium
i
2/23/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$31.00Medium
i
2/2/2018Jefferies Financial GroupReiterated RatingHold ➝ NeutralLow
i
1/17/2018Canaccord GenuityReiterated RatingBuyLow
i
1/16/2018Needham & Company LLCReiterated RatingBuy$32.00Low
i
1/10/2018BarclaysReiterated RatingBuy$32.00Low
i
1/5/2018Royal Bank of CanadaUpgradeOutperform ➝ Top PickMedium
i
1/3/2018Evercore ISIInitiated CoverageIn ➝ In-Line$27.00Medium
i
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00Low
i
12/8/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$25.04 ➝ $32.00Low
i
12/4/2017SunTrust BanksSet Price TargetBuy$33.00Low
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
11/30/2017CowenSet Price TargetBuy$31.00Low
i
Rating by Josh Jennings at Cowen Inc
11/30/2017BTIG ResearchUpgradeNeutral ➝ Buy$31.00Medium
i
11/29/2017BMO Capital MarketsReiterated RatingBuy$31.00Medium
i
11/29/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
i
11/29/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/29/2017Canaccord GenuityLower Price TargetBuy ➝ Buy$36.00 ➝ $35.00High
i
11/7/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
i
10/31/2017SunTrust BanksSet Price TargetBuy$34.00N/A
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $32.00N/A
i
10/24/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$36.00N/A
i
10/13/2017BMO Capital MarketsReiterated RatingBuy$30.00N/A
i
10/3/2017Needham & Company LLCReiterated RatingBuy$32.00Low
i
10/2/2017SunTrust BanksReiterated RatingBuy$34.00Medium
i
9/25/2017Stifel NicolausReiterated RatingBuy$32.00Low
i
9/7/2017Jefferies Financial GroupReiterated RatingHoldLow
i
9/1/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
i
8/9/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/1/2017UBS GroupReiterated RatingBuy$30.00 ➝ $31.00Low
i
7/30/2017Stifel NicolausReiterated RatingBuy$32.00Medium
i
7/28/2017OppenheimerSet Price TargetHold$29.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/28/2017CowenReiterated RatingBuy$31.00 ➝ $32.00Low
i
7/17/2017CowenReiterated RatingOutperform$31.00Low
i
7/12/2017Royal Bank of CanadaReiterated RatingBuy$31.00Low
i
6/28/2017JPMorgan Chase & Co.Reiterated RatingOverweight$27.00 ➝ $31.00Low
i
6/28/2017Stifel NicolausBoost Price TargetHold$30.00 ➝ $32.00Low
i
6/28/2017Jefferies Financial GroupReiterated RatingHold$28.00Low
i
6/28/2017OppenheimerReiterated RatingHoldLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/28/2017BarclaysBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $31.00Low
i
6/22/2017Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $32.00Low
i
6/21/2017BMO Capital MarketsReiterated RatingBuy$30.00Low
i
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 ➝ $31.00Low
i
6/9/2017Royal Bank of CanadaReiterated RatingOurperform$31.00 ➝ $29.00Low
i
6/9/2017Royal Bank of CanadaBoost Price TargetOutperform$29.00 ➝ $31.00Low
i
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$28.00Low
i
4/28/2017Stifel NicolausBoost Price TargetBuy$28.00 ➝ $30.00Low
i
4/28/2017CowenBoost Price TargetOutperform$29.00 ➝ $31.00Low
i
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 ➝ $28.50Low
i
4/28/2017OppenheimerSet Price TargetHold$27.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/27/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $30.00Low
i
4/12/2017GuggenheimReiterated RatingBuyLow
i
Rating by Christopher Pasquale at Guggenheim
4/7/2017Jefferies Financial GroupBoost Price TargetHold$26.00 ➝ $28.00Low
i
2/23/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/23/2017Needham & Company LLCReiterated RatingBuy$29.00N/A
i
2/23/2017Northland SecuritiesReiterated RatingPositiveN/A
i
2/5/2017BTIG ResearchReiterated RatingHoldN/A
i
2/3/2017OppenheimerSet Price TargetHold$25.00 ➝ $26.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/3/2017Jefferies Financial GroupReiterated RatingHold$26.00N/A
i
2/2/2017Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $29.00N/A
i
1/8/2017BTIG ResearchReiterated RatingNeutralN/A
i
10/14/2016Royal Bank of CanadaReiterated RatingOutperform$28.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
10/6/2016CitigroupBoost Price TargetBuy$28.00 ➝ $29.00N/A
i
9/1/2016ArgusUpgradeHold ➝ Buy$23.82 ➝ $33.00N/A
i
Rating by David Toung at Argus
8/3/2016CitigroupBoost Price TargetBuy$26.00 ➝ $28.00N/A
i
7/31/2016Evercore ISIReiterated RatingBuy$25.50 ➝ $26.00N/A
i
7/29/2016Royal Bank of CanadaReiterated RatingBuy$28.00N/A
i
7/29/2016JPMorgan Chase & Co.Boost Price TargetOverweight$24.00 ➝ $27.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/29/2016Credit Suisse GroupReiterated RatingBuyN/A
i
7/29/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/29/2016Jefferies Financial GroupBoost Price TargetHold$21.00 ➝ $24.00N/A
i
7/29/2016WedbushBoost Price TargetNeutral$23.00 ➝ $25.00N/A
i
7/29/2016Needham & Company LLCBoost Price TargetBuy$26.00 ➝ $28.00N/A
i
Rating by Michael Matson at Needham & Company LLC
7/28/2016BenchmarkBoost Price TargetBuy$25.00 ➝ $31.00N/A
i
Rating by Jan Wald at Benchmark Co.
7/17/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/5/2016UBS GroupReiterated RatingBuy$25.00N/A
i
Rating by Matt Miksic at UBS Group AG
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
6/17/2016SVB LeerinkReiterated RatingBuy$25.50 ➝ $27.50N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
6/8/2016GuggenheimInitiated CoverageBuy$26.00N/A
i
5/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
5/23/2016BTIG ResearchDowngradeBuy ➝ Neutral$24.20N/A
i
Rating by Sean Lavin at BTIG Research
(Data available from 5/18/2016 forward)
Boston Scientific logo
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Read More

Today's Range

Now: $41.72
$41.23
$41.82

50 Day Range

MA: $41.18
$38.22
$44.24

52 Week Range

Now: $41.72
$32.99
$44.63

Volume

5,549,238 shs

Average Volume

9,200,281 shs

Market Capitalization

$59.28 billion

P/E Ratio

15.98

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Boston Scientific?

The following Wall Street analysts have issued reports on Boston Scientific in the last twelve months: Atlantic Securities, BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for BSX.

What is the current price target for Boston Scientific?

17 Wall Street analysts have set twelve-month price targets for Boston Scientific in the last year. Their average twelve-month price target is $46.53, suggesting a possible upside of 11.5%. Atlantic Securities has the highest price target set, predicting BSX will reach $52.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $43.00 for Boston Scientific in the next year.
View the latest price targets for BSX.

What is the current consensus analyst rating for Boston Scientific?

Boston Scientific currently has 4 hold ratings, 12 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BSX will outperform the market and that investors should add to their positions of Boston Scientific.
View the latest ratings for BSX.

What other companies compete with Boston Scientific?

How do I contact Boston Scientific's investor relations team?

Boston Scientific's physical mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 683-4000 and its investor relations email address is [email protected] The official website for Boston Scientific is www.bostonscientific.com.